Teladoc Health (TDOC) Set to Announce Quarterly Earnings on Wednesday

Key Points

• Teladoc Health is expected to report Q3 2026 results after market close on October 28. Analysts forecast a loss of $0.2171 per share and revenue of $588.44 million, compared with company guidance of a $0.20–$0.30 per-share loss.
• In the prior quarter, Teladoc reported a $0.21-per-share loss, beating estimates, but revenue of $606.93 million missed expectations and declined 4% year over year. Analysts expect full-year EPS of approximately negative $0.92.
• TDOC shares were trading around $6.20, while analysts held a consensus “Hold” rating and an average price target of $7.54. Price targets remain mixed, ranging from $7.50 to $10.50 among recently commenting firms.

Teladoc Health (NYSE:TDOC - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Teladoc Health to post earnings of ($0.2171) per share and revenue of $588.44 million for the quarter. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. Interested persons may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 5:00 PM ET.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. The firm had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%. The business's quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.19) earnings per share. On average, analysts expect Teladoc Health to post ($0.92) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

Teladoc Health Trading Up 8.1%

Teladoc Health stock opened at $6.20 on Wednesday. The stock has a fifty day moving average price of $6.18 and a 200 day moving average price of $6.89. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.89. The firm has a market capitalization of $1.13 billion, a P/E ratio of -6.26 and a beta of 2.14.

Wall Street Analysts Forecast Growth

Several analysts have commented on TDOC shares. Citigroup lowered their price target on Teladoc Health from $11.00 to $7.50 and set a "neutral" rating for the company in a report on Monday, August 3rd. Canaccord Genuity Group cut their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Bank of America raised their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a "buy" rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a report on Wednesday, August 19th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Teladoc Health has a consensus rating of "Hold" and an average target price of $7.54.

Insiders Place Their Bets

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the business's stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the sale, the chief executive officer owned 465,535 shares of the company's stock, valued at approximately $2,839,763.50. The trade was a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.70% of the company's stock.

Teladoc Health Company Profile

Teladoc Health, Inc NYSE: TDOC provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company's offerings include Teladoc's telehealth services, BetterHelp's online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.